



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C12N 15/37, 15/86, C07K 14/025, A61K 48/00		A2	(11) International Publication Number: WO 00/14244
		(43) International Publication Date:	16 March 2000 (16.03.00)
(21) International Application Number: PCT/CA99/00807 (22) International Filing Date: 3 September 1999 (03.09.99) (30) Priority Data: 60/099,291 ✓ 4 September 1998 (04.09.98) US (71) Applicant (for all designated States except US): CONNAUGHT LABORATORIES LIMITED [CA/CA]; 1755 Steeles Avenue, Toronto, Ontario M2R 3T4 (CA). (72) Inventors; and (75) Inventors/Applicants (for US only): GAJEWCZYK, Diane, M. [CA/CA]; 21 Crafton Avenue, Toronto, Ontario M6R 1C3 (CA). PERSSON, Roy [CA/CA]; Unit 604, 7 Bishop Avenue, North York, Ontario M2M 4J4 (CA). YAO, Fei-Long [CN/CA]; 81 Elsa Vineway, North York, Ontario M2J 4H8 (CA). CAO, Shi-Xian [CA/CA]; Apt. 408, 716 The West Mall, Etobicoke, Ontario M9C 4X6 (CA). KLEIN, Michel, H. [CA/CA]; 16 Munro Boulevard, Willowdale, Ontario M2P 1B9 (CA). TARTAGLIA, James [US/US]; 7 Christina Drive, Schenectady, NY 12303 (US). MOINGEON, Phillipe [FR/FR]; Chemin Saint Jean, F- Pommiers (FR). ROVIN-SKI, Benjamin [CA/CA]; 70 Winding Lane, Thornhill, Ontario L4J 5H6 (CA).		(74) Agent: STEWART, Michael, I.; Sim & McBurney, 6th floor, 330 University Avenue, Toronto, Ontario M5G 1R7 (CA). (81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published Without international search report and to be republished upon receipt of that report.	
(54) Title: TREATMENT OF CERVICAL CANCER			
(57) Abstract			
<p>Vectors for DNA immunization against cervical cancer comprise a nucleic acid molecule encoding at least one non-toxic T-cell epitope of the E6 and/or E7 antigens of a strain of human papilloma virus (HPV) associated with cervical cancer, such as HPV-16, and a promoter operatively coupled to the nucleic acid molecule for expression of the nucleic acid molecule in a host to which the vector is administered.</p>			